Centerpoint Advisors’s Haemonetics HAE Stock Holding History

Centerpoint Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25	Closed	-$2K	–	292
2018 Q2	$2K	Buy	+25	New	+$2.11K	﹤0.01%	301

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Centerpoint Advisors's HAE Position: Q3 2018 in Review

Centerpoint Advisors sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 25 shares — an estimated $2K sold.

Centerpoint Advisors first reported a position in HAE in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

Centerpoint Advisors reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
Centerpoint Advisors sold 25 Haemonetics shares in Q3 2018, an estimated $2K.
Centerpoint Advisors first reported a position in Haemonetics in Q2 2018 and held it in 1 quarter.
Centerpoint Advisors's Haemonetics position peaked at $2K in Q2 2018.
292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Centerpoint Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.